Andrea Mogavero, Resident Physician in Medical Oncology at Azienda Ospedaliero Universitaria San Luigi Gonzaga, shared a post on LinkedIn:
“The role of first-line Osimertinib in patients with uncommon EGFR mutations remains a subject of ongoing debate.
We investigated its efficacy in a cohort of NSCLC patients harboring uncommon EGFR mutations, with a particular focus on Exon 19 deletion-insertion (Delins) variants, within a real-world setting using the Italian ATLAS platform.
Many thanks to AIOM | Associazione Italiana di Oncologia Medica for providing this opportunity.”
More posts on OncoDaily.